Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mucosal healing in inflammatory bowel disease: where do we stand?

Literature DB >> 20886319

Mucosal healing in inflammatory bowel disease: where do we stand?

Abstract

The definition of remission in Crohn's disease and ulcerative colitis has evolved to include mucosal healing as a measure of treatment efficacy. Randomized, controlled trials have demonstrated mucosal healing is attainable with the current arsenal of therapies available to treat inflammatory bowel disease. Mucosal healing has been shown to reduce the likelihood of clinical relapse, reduce the risk of future surgeries, and reduce hospitalizations. This review focuses on the latest studies addressing clinical outcomes of mucosal healing in the clinical trial and practice setting.

Entities: Disease

Mesh：

Substances：

Year: 2010 PMID： 20886319 DOI： 10.1007/s11894-010-0146-8

Source DB: PubMed Journal: Curr Gastroenterol Rep ISSN： 1522-8037

54 in total

1. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors: Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal: Gut Date: 2011-01-05 Impact factor: 23.059

2. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors: A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal: Gut Date: 2005-08 Impact factor: 23.059

3. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.

Authors: Stephen B Hanauer; William J Sandborn; Asher Kornbluth; Seymour Katz; Michael Safdi; Scott Woogen; Gino Regalli; Chyon Yeh; Nancy Smith-Hall; Funmilay Ajayi
Journal: Am J Gastroenterol Date: 2005-11 Impact factor: 10.864

4. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy.

Authors: Matthieu Allez; Marc Lemann; Joëlle Bonnet; Pierre Cattan; Raymond Jian; Robert Modigliani
Journal: Am J Gastroenterol Date: 2002-04 Impact factor: 10.864

5. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis.

Authors: J Powell-Tuck; D W Day; N A Buckell; J Wadsworth; J E Lennard-Jones
Journal: Dig Dis Sci Date: 1982-06 Impact factor: 3.199

6. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors: D Rachmilewitz
Journal: BMJ Date: 1989-01-14

7. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors: J Y Mary; R Modigliani
Journal: Gut Date: 1989-07 Impact factor: 23.059

8. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.

Authors: Andrea Cassinotti; Giovanni C Actis; Piergiorgio Duca; Alessandro Massari; Elisabetta Colombo; Elisa Gai; Vito Annese; Giuseppe D'Albasio; Gianpiero Manes; Simon Travis; Gabriele Bianchi Porro; Sandro Ardizzone
Journal: Am J Gastroenterol Date: 2009-07-21 Impact factor: 10.864

9. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682

10. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity.

Authors: F Carbonnel; A Lavergne; M Lémann; A Bitoun; P Valleur; P Hautefeuille; A Galian; R Modigliani; J C Rambaud
Journal: Dig Dis Sci Date: 1994-07 Impact factor: 3.199

11 in total

1. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.

Authors: H Yu; D MacIsaac; J J Wong; Z M Sellers; A A Wren; R Bensen; C Kin; K T Park
Journal: Aliment Pharmacol Ther Date: 2017-11-22 Impact factor: 8.171

Review 2. Quality improvement in pediatric inflammatory bowel disease: moving forward to improve outcomes.

Authors: Pauline Quach; Geoffrey C Nguyen; Eric I Benchimol
Journal: World J Gastroenterol Date: 2013-10-14 Impact factor: 5.742

Review 3. Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic.

Authors: M C Ammons; V Copié
Journal: Biofouling Date: 2013 Impact factor: 3.209

4. Analysis of Antimicrobial and Antibiofilm Activity of Human Milk Lactoferrin Compared to Bovine Lactoferrin against Multidrug Resistant and Susceptible Acinetobacter baumannii Clinical Isolates.

Authors: Tyra M Avery; RaNashia L Boone; Jacky Lu; Sabrina K Spicer; Miriam A Guevara; Rebecca E Moore; Schuyler A Chambers; Shannon D Manning; Leon Dent; Dana Marshall; Steven M Damo; Steven D Townsend; Jennifer A Gaddy
Journal: ACS Infect Dis Date: 2021-06-09 Impact factor: 5.084

5. Anterior Gradient Protein 2 Promotes Mucosal Repair in Pediatric Ulcerative Colitis.

Authors: Xiaolin Ye; Jie Wu; Jing Li; Hongyu Wang
Journal: Biomed Res Int Date: 2021-05-18 Impact factor: 3.411

Review 6. The impact of biological interventions for ulcerative colitis on health-related quality of life.

Authors: Katie LeBlanc; Mahmoud H Mosli; Claire E Parker; John K MacDonald
Journal: Cochrane Database Syst Rev Date: 2015-09-22

Review 7. Worms, flies and four-legged friends: the applicability of biological models to the understanding of intestinal inflammatory diseases.

Authors: Joyce Lin; David J Hackam
Journal: Dis Model Mech Date: 2011-06-13 Impact factor: 5.758